
Andreas A Kammerlander

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6048203/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impact of afterload and infiltration on coexisting aortic stenosis and transthyretin amyloidosis. Heart, 2022, 108, 67-72.	1.2	8
2	Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy. European Heart Journal Cardiovascular Imaging, 2022, 23, 767-780.	0.5	38
3	Transcatheter Versus Surgical Valve Repair in Patients with Severe Mitral Regurgitation. Journal of Personalized Medicine, 2022, 12, 90.	1.1	2
4	Cerebral Protection in TAVR—Can We Do Without? A Real-World All-Comer Intention-to-Treat Study—Impact on Stroke Rate, Length of Hospital Stay, and Twelve-Month Mortality. Journal of Personalized Medicine, 2022, 12, 320.	1.1	5
5	Bioimpedance Spectroscopy Reveals Important Association of Fluid Status and <scp> T ₁ </scp> â€Mapping by Cardiovascular Magnetic Resonance. Journal of Magnetic Resonance Imaging, 2022, ,	1.9	1
6	Prognostic impact of left atrial function in heart failure with preserved ejection fraction in sinus rhythm vs. persistent atrial fibrillation. ESC Heart Failure, 2022, 9, 465-475.	1.4	5
7	Gender differences in cardiology—More questions than answers. Wiener Klinische Wochenschrift, 2022, 134, 259.	1.0	1
8	The Complexity of Subtle Cardiac Tracer Uptake on Bone Scintigraphy. JACC: Cardiovascular Imaging, 2022, 15, 1516-1518.	2.3	9
9	Comparison of Hepatic Tissue Characterization between T1-Mapping and Non-Contrast Computed Tomography. Journal of Clinical Medicine, 2022, 11, 2863.	1.0	0
10	Invasive Hemodynamic Assessment and Procedural Success of Transcatheter Tricuspid Valve Repair—Important Factors for Right Ventricular Remodeling and Outcome. Frontiers in Cardiovascular Medicine, 2022, 9, .	1.1	7
11	Prevalence and Outcomes of Cardiac Amyloidosis in All-Comer Referrals for Bone Scintigraphy. Journal of Nuclear Medicine, 2022, 63, 1906-1911.	2.8	13
12	Reverse Remodeling Following Valve Replacement in Coexisting Aortic Stenosis and Transthyretin Cardiac Amyloidosis. Circulation: Cardiovascular Imaging, 2022, 15, .	1.3	12
13	Prevalence and Outcomes of Concomitant Aortic Stenosis and CardiacÂAmyloidosis. Journal of the American College of Cardiology, 2021, 77, 128-139.	1.2	187
14	Effects of Levosimendan on cardiac function, size and strain in heart failure patients. International Journal of Cardiovascular Imaging, 2021, 37, 1063-1071.	0.7	3
15	Volume Status Impacts CMR–Extracellular Volume Measurements and Outcome in AS Undergoing TAVR. JACC: Cardiovascular Imaging, 2021, 14, 516-518.	2.3	7
16	Association of Metabolic Phenotypes With Coronary Artery Disease and Cardiovascular Events in Patients With Stable Chest Pain. Diabetes Care, 2021, 44, 1038-1045.	4.3	18
17	Fluid overload in patients undergoing TAVR: what we can learn from the nephrologists. ESC Heart Failure, 2021, 8, 1408-1416.	1.4	7
18	Transcatheter treatment by valve-in-valve and valve-in-ring implantation for prosthetic tricuspid valve dysfunction. Wiener Klinische Wochenschrift, 2021, 133, 780-785.	1.0	4

#	Article	IF	CITATIONS
19	Safety and image quality of cardiovascular magnetic resonance imaging in patients with retained epicardial pacing wires after heart transplantation. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 24.	1.6	4
20	Discordance of High-Sensitivity Troponin Assays in Patients With Suspected Acute Coronary Syndromes. Journal of the American College of Cardiology, 2021, 77, 1487-1499.	1.2	18
21	Sex Differences in the Associations of Visceral Adipose Tissue and Cardiometabolic and Cardiovascular Disease Risk: The Framingham Heart Study. Journal of the American Heart Association, 2021, 10, e019968.	1.6	33
22	Clinical Impact of Pre-Procedural Percutaneous Coronary Intervention in Low- and Intermediate-Risk Transcatheter Aortic Valve Replacement Recipients. Journal of Personalized Medicine, 2021, 11, 633.	1.1	1
23	New risk stratification after colorectal polypectomy reduces burden of surveillance without increasing mortality. United European Gastroenterology Journal, 2021, 9, 947-954.	1.6	7
24	Heart Failure with Preserved Ejection Fraction after Leftâ€sided Valve Surgery: Prevalent and Relevant. European Journal of Heart Failure, 2021, , .	2.9	5
25	Association of Adenoma Detection Rate and Adenoma Characteristics With Colorectal Cancer Mortality After Screening Colonoscopy. Clinical Gastroenterology and Hepatology, 2021, 19, 1890-1898.	2.4	18
26	Right ventricular function and outcome in patients undergoing transcatheter aortic valve replacement. European Heart Journal Cardiovascular Imaging, 2021, 22, 1295-1303.	0.5	12
27	Cerebral protection in TAVR $\hat{a} \in$ " can we do without? Impact on stroke rate, length of hospital stay and 12-month mortality. European Heart Journal, 2021, 42, .	1.0	Ο
28	Cardiac imaging in tafamidis-treatment patients with transthyretin amyloid cardiomyopathy. European Heart Journal, 2021, 42, .	1.0	0
29	Prevalence of cardiac amyloidosis in patients undergoing transcatheter edge-to edge mitral valve repair. European Heart Journal, 2021, 42, .	1.0	Ο
30	Convolutional Neural Networks for Fully Automated Diagnosis of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging. Journal of Personalized Medicine, 2021, 11, 1268.	1.1	5
31	Determinants of Bioprosthetic AorticÂValve Degeneration. JACC: Cardiovascular Imaging, 2020, 13, 345-353.	2.3	27
32	Native T1 time of right ventricular insertion points by cardiac magnetic resonance: relation with invasive haemodynamics and outcome in heart failure with preserved ejection fraction. European Heart Journal Cardiovascular Imaging, 2020, 21, 683-691.	0.5	22
33	Persistent atrial fibrillation in heart failure with preserved ejection fraction: Prognostic relevance and association with clinical, imaging and invasive haemodynamic parameters. European Journal of Clinical Investigation, 2020, 50, e13184.	1.7	10
34	International Multi-Center Analysis of In-hospital Morbidity and Mortality of Low-Voltage Electrical Injuries. Frontiers in Medicine, 2020, 7, 590758.	1.2	7
35	Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. Wiener Klinische Wochenschrift, 2020, 132, 742-761.	1.0	31
36	COVID-19: frequently asked questions to the cardiologist. Wiener Klinische Wochenschrift, 2020, 132, 690-692.	1.0	4

#	Article	IF	CITATIONS
37	Sex Differences in Left Ventricular Remodeling and Outcomes in Chronic Aortic Regurgitation. Journal of Clinical Medicine, 2020, 9, 4100.	1.0	3
38	Feature Tracking of Global Longitudinal Strain by Using Cardiovascular MRI Improves Risk Stratification in Heart Failure with Preserved Ejection Fraction. Radiology, 2020, 296, 290-298.	3.6	34
39	Impact of Left Atrial Phasic Function in HeartÂFailure With Preserved Ejection Fraction. JACC: Cardiovascular Imaging, 2020, 13, 2254-2255.	2.3	4
40	Lightâ€chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome. European Journal of Heart Failure, 2020, 22, 1852-1862.	2.9	82
41	Feature Tracking by Cardiovascular Magnetic Resonance Imaging. JACC: Cardiovascular Imaging, 2020, 13, 948-950.	2.3	9
42	Gender-specific differences in valvular heart disease. Wiener Klinische Wochenschrift, 2020, 132, 61-68.	1.0	29
43	Save your brain – does the sentinel cerebral protection device work?. European Heart Journal, 2020, 41, .	1.0	0
44	HIGH RIGHT ATRIAL PRESSURE AND BLEEDING EVENTS IN ORALLY ANTICOAGULATED PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION. Journal of the American College of Cardiology, 2019, 73, 725.	1.2	0
45	Patients with Heart Failure and Preserved Ejection Fraction Are at Risk of Gastrointestinal Bleeding. Journal of Clinical Medicine, 2019, 8, 1240.	1.0	11
46	Global Longitudinal Strain by CMRÂFeatureÂTracking Is Associated WithÂOutcome in HFPEF. JACC: Cardiovascular Imaging, 2019, 12, 1585-1587.	2.3	19
47	The Authors Reply:. JACC: Cardiovascular Imaging, 2019, 12, 2284.	2.3	1
48	Angs (Angiotensins) of the Alternative Renin-Angiotensin System Predict Outcome in Patients With Heart Failure and Preserved Ejection Fraction. Hypertension, 2019, 74, 285-294.	1.3	26
49	26Bioimpedance spectroscopy reveals association of fluid status and extracellular volume by cardiovascular magnetic resonance. European Heart Journal Cardiovascular Imaging, 2019, 20, .	0.5	0
50	With a grain of salt: Sodium levels in heart failure. International Journal of Cardiology, 2019, 290, 125-126.	0.8	3
51	Riociguat for the treatment of transthyretin cardiac amyloidosis: data from a named patient use program in Austria. Pulmonary Circulation, 2019, 9, 1-9.	0.8	1
52	What is normal? AÂcentral question in the application of CMR mapping techniques. Wiener Klinische Wochenschrift, 2019, 131, 141-142.	1.0	0
53	Serum levels of gamma-glutamyltransferase predict outcome in heart failure with preserved ejection fraction. Scientific Reports, 2019, 9, 18541.	1.6	10
54	Syncope. JACC: Cardiovascular Imaging, 2019, 12, 225-232.	2.3	22

#	Article	IF	CITATIONS
55	Diagnostic and Prognostic Utility of Cardiac Magnetic Resonance Imaging inÂAortic Regurgitation. JACC: Cardiovascular Imaging, 2019, 12, 1474-1483.	2.3	59
56	Mechanisms of heart failure in transthyretin vs. light chain amyloidosis. European Heart Journal Cardiovascular Imaging, 2019, 20, 512-524.	0.5	26
57	Impact of Systemic Volume Status on Cardiac Magnetic Resonance T1 Mapping. Scientific Reports, 2018, 8, 5572.	1.6	17
58	Gender-related differences in heart failure with preserved ejection fraction. Scientific Reports, 2018, 8, 1080.	1.6	60
59	Extracellular volume quantification by cardiac magnetic resonance imaging without hematocrit sampling. Wiener Klinische Wochenschrift, 2018, 130, 190-196.	1.0	18
60	P2581Extracellular volume by cmr for risk assessment in patients undergoing mitral valve surgery. European Heart Journal, 2018, 39, .	1.0	0
61	FP539IMPACT OF SYSTEMIC VOLUME STATUS ON CARDIAC MAGNETIC RESONANCE T1 MAPPING IN HEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2018, 33, i221-i221.	0.4	Ο
62	Cardiac Magnetic Resonance T1 Mapping in Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2018, 11, 1924-1926.	2.3	34
63	Tricuspid valve replacement: results of an orphan procedure - which is the best prosthesis?. Journal of Cardiovascular Surgery, 2018, 59, 626-632.	0.3	5
64	Fluid status and outcome in patients with heart failure and preserved ejection fraction. International Journal of Cardiology, 2017, 230, 476-481.	0.8	26
65	Cardiac extracellular matrix is associated with adverse outcome in patients with chronic heart failure. European Journal of Heart Failure, 2017, 19, 502-511.	2.9	17
66	Diameter of the Pulmonary Artery in Relation to the Ascending Aorta: Association with Cardiovascular Outcome. Radiology, 2017, 284, 685-693.	3.6	11
67	Wedge Pressure Rather Than LeftÂVentricular End-Diastolic Pressure Predicts Outcome in Heart Failure WithÂPreserved Ejection Fraction. JACC: Heart Failure, 2017, 5, 795-801.	1.9	58
68	Modes of death in patients with heart failure and preserved ejection fraction. International Journal of Cardiology, 2017, 228, 422-426.	0.8	42
69	Presence of Âîsolated´ tricuspid regurgitation should prompt the suspicion of heart failure with preserved ejection fraction. PLoS ONE, 2017, 12, e0171542.	1.1	34
70	Clinical Neuropathology image 3-2017: CNS involvement in systemic amyloidosis restricted to the choroid plexus. , 2017, 36, 100-101.		0
71	Functional Status, Pulmonary Artery Pressure, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2016, 68, 189-199.	1.2	77
72	When it rains, it pours: Peripartum cardiomyopathy with features of leftâ€ventricular noncompaction in a hemodialysis patient. Hemodialysis International, 2016, 20, E14-E17.	0.4	2

#	Article	IF	CITATIONS
73	Interstitial Fibrosis, Functional Status, and Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation: Cardiovascular Imaging, 2016, 9, .	1.3	113
74	Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction. Wiener Klinische Wochenschrift, 2016, 128, 882-889.	1.0	20
75	The right heart in heart failure with preserved ejection fraction: insights from cardiac magnetic resonance imaging and invasive haemodynamics. European Journal of Heart Failure, 2016, 18, 71-80.	2.9	114
76	Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2016, 18, 89-93.	2.9	43
77	T1 Mapping by CMR Imaging. JACC: Cardiovascular Imaging, 2016, 9, 14-23.	2.3	164
78	Prognostic Significance and DeterminantsÂof the 6-Min Walk Test inÂPatients WithÂHeart Failure and Preserved EjectionÂFraction. JACC: Heart Failure, 2015, 3, 459-466.	1.9	48
79	Pulmonary artery to aorta ratio for the detection of pulmonary hypertension: cardiovascular magnetic resonance and invasive hemodynamics in heart failure with preserved ejection fraction. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 79.	1.6	43
80	Coronary Neutrophil Extracellular Trap Burden and Deoxyribonuclease Activity in ST-Elevation Acute Coronary Syndrome Are Predictors of ST-Segment Resolution and Infarct Size. Circulation Research, 2015, 116, 1182-1192.	2.0	373
81	Prevalence and prognostic significance of right ventricular systolic dysfunction in heart failure with preserved ejection fraction. Insights from a cardiac magnetic resonance imaging study. Journal of Cardiovascular Magnetic Resonance, 2015, 17, O33.	1.6	1
82	Extracellular matrix expansion by cardiac magnetic resonance T1 mapping- validation with myocardial biopsy. Journal of Cardiovascular Magnetic Resonance, 2015, 17, P308.	1.6	2
83	Diastolic Pressure GradientÂPredicts Outcome inÂPatients With Heart Failure andÂPreserved EjectionÂFraction. Journal of the American College of Cardiology, 2015, 66, 1308-1310.	1.2	18
84	Outcome in Heart Failure with Preserved Ejection Fraction: The Role of Myocardial Structure and Right Ventricular Performance. PLoS ONE, 2015, 10, e0134479.	1.1	26
85	Prognostic Impact of Tricuspid Regurgitation in Patients Undergoing Aortic Valve Surgery for Aortic Stenosis. PLoS ONE, 2015, 10, e0136024.	1.1	28
86	Right Ventricular Dysfunction, But Not Tricuspid Regurgitation, Is Associated With Outcome Late After Left Heart ValveÂProcedure. Journal of the American College of Cardiology, 2014, 64, 2633-2642.	1.2	128
87	Factors Determining Patient-Prosthesis Mismatch after Aortic Valve Replacement – A Prospective Cohort Study. PLoS ONE, 2013, 8, e81940.	1.1	28
88	Standardized measurement of abdominal muscle by computed tomography: association with cardiometabolic risk in the Framingham Heart Study. European Radiology, 0, , .	2.3	2